Target officially unveils Kodak photo kiosks with Facebook connectivity
MINNEAPOLIS Target shoppers now can enjoy social network connectivity at in-store Kodak picture kiosks.
As previously reported in June, Target guests now will be able to create a variety of stunning photo products ranging from standard prints to personalized photo keepsakes, such as Kodak photo books, collages, calendars, holiday and greeting cards, Kodak picture movie DVDs and more.
With more than 500 million users and 3 billion photos uploaded to Facebook each month, Kodak picture kiosks enabled with social network connectivity give Target guests a convenient way to easily print online photos in stores.
“Kodak has always been a leader in innovative photography solutions, and Target is proud to be the first mass retailer to offer this creative solution nationwide,” said Mark Schindele, SVP merchandising at Target. “We know our guests are increasingly sharing their photos online, and Kodak Picture Kiosks with Social Network Connectivity allow them access to their favorite photos along with the convenience of printing the images during their regular Target shopping trip.”
Big Y finalizing purchase of Conn.-based A&P stores
SPRINGFIELD, Mass. Big Y reportedly is closing its deal to acquire seven A&P stores in northern Connecticut.
The Springfield, Mass.-based retailer said the sale will be completed on Nov. 1, according to the Boston Herald. Big Y owns stores in Massachusetts and Connecticut and has served these markets for nearly 75 years.
As previously reported by Drug Store News, grocer A&P announced in September an agreement with Big Y to sell the stores as part of its turnaround strategy.
“We continue to evaluate our operating footprint and its alignment with our turnaround strategy. These seven stores were clearly outside of our core markets, and their sale was necessary,” Sam Martin, president and CEO of A&P, stated at the time.
NeurogesX seeks expanded approval for Qutenza
SAN MATEO, Calif. A company that develops drugs for pain is hoping to get approval of one of its drugs for a pain condition associated with HIV.
NeurogesX announced Monday that it would seek Food and Drug Administration approval for the drug Qutenza (capsaicin) as a treatment for HIV-associated neuropathy, also called HIV-AN or HIV-distal sensory polyneuropathy, in the first half of 2011. The drug, a patch, already is approved for post-herpetic neuralgia. HIV-AN results from injury to sensory neurons by HIV virus proteins, the body’s immune response to the virus and some drugs used to treat it.
“As a company, we are focused on addressing unmet medical needs in pain and have made significant progress toward this goal with the U.S. launch of Qutenza,” NeurogesX president and CEO Anthony DiTonno said. “Our decision to submit a supplemental [application] to address the HIV-AN patient population is important as there are currently no FDA-approved treatments for HIV-AN.”